Supriya Lifescience Q1 FY27 Results: Revenue up 31% YoY, PAT drops 31%

Revenue growth above 20%EBITDA margin compressionResults View source PDF Explain this filing

SUPRIYA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹813.50

prior close

₹745.00

announcement price

After-mkt

timing

Nifty Microcap 250market+0.1%-2.8% vs market

Pharmaceuticals peers, median of 166sector-0.4%-2.4% vs sector

On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+4.0

10m

+5.1

15m

+3.4

30m

+5.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8+0.1-2.8-0.4-2.4

Next day

-4.0+0.2-4.2-0.3-3.7

-1.2+0.6-1.8-0.5-0.7

-3.1-0.0-3.1-1.3-1.8

-0.2+0.5-0.7-0.9+0.7

-0.9+0.8-1.7-0.4-0.5

-2.8+0.6-3.3-0.9-1.9

15d

+4.0+1.3+2.7+0.0+4.0

+7.4-1.4+8.8-0.1+7.6

+6.9-0.6+7.5-2.8+9.7

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 166Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved Q1 FY27 unaudited results ended June 30 2026. Revenue from operations rose 30.8% year on year to Rs 189.75 crore from Rs 145.07 crore. However, profit after tax fell 30.9% to Rs 24.04 crore versus Rs 34.79 crore. Margins compressed sharply due to higher material and operating costs. EPS at Rs 2.99 versus Rs 4.32. Auditor gave a clean limited review. An export shipment was detained by customs and recognized as sale.

Likely market impact

Strong revenue growth but steep margin compression and lower profits may weigh on the stock in the near term.